Cart
sales@molnova.com
p-(2-Methoxyethyl) phenol
CAS No. 56718-71-9
p-(2-Methoxyethyl) phenol( —— )
Catalog No. M15064 CAS No. 56718-71-9
An important kind of pharmaceutical intermediates, mainly used in the manufacture of effective drugs in the treatment of cardiovascular disease metoprolol.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 45 | In Stock |
|
| 10MG | 54 | In Stock |
|
| 25MG | 76 | In Stock |
|
| 50MG | 98 | In Stock |
|
| 100MG | 129 | In Stock |
|
| 200MG | 181 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Namep-(2-Methoxyethyl) phenol
-
NoteResearch use only, not for human use.
-
Brief DescriptionAn important kind of pharmaceutical intermediates, mainly used in the manufacture of effective drugs in the treatment of cardiovascular disease metoprolol.
-
DescriptionAn important kind of pharmaceutical intermediates, mainly used in the manufacture of effective drugs in the treatment of cardiovascular disease metoprolol.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number56718-71-9
-
Formula Weight152.19
-
Molecular FormulaC9H12O2
-
Purity>98% (HPLC)
-
SolubilitySoluble in Ethanol, slightly soluble in Water
-
SMILESCOCCC1=CC=C(O)C=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
GPI-1485
GPI-1485 (GM1485) is a nonimmunosuppressive immunophilin ligand, promoting neurofunctional improvement and neural regeneration following stroke.
-
Influenza NP (482 - ...
Influenza NP (482 - 489)
-
NADP disodium salt
NADP disodium salt is a nicotinamide adenine dinucleotide. NADP disodium salt is a key redox cofactor for electron transfer in the metabolism, serves as an electron carrier in a number of reactions, being alternately oxidized (NADP+) and reduced (NADPH).
